share_log

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

JonesTrading Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $12

Jones Trading以買入評級啟動Inhibikase治療藥物的覆蓋範圍,宣佈目標價為12美元
Benzinga Real-time News ·  2021/07/15 09:32

JonesTrading analyst Soumit Roy initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $12.

Jones Trading分析師Soumit Roy以買入評級啟動Inhibikase治療公司(納斯達克市場代碼:IKT)的報道,並宣佈目標價為12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論